HIV DART 2000, Frontiers in Drug Development for Antiretroviral Therapies
	Ritz-Carlton, San Juan Hotel , Isla Verde, Puerto Rico December 17-21, 2000
	Conference Program Highlights Opening session will comprise a presentation by Dr Anthony Fauci, NIAID, National Institutes of Health on Sunday, December 17, 2000 at 2:00 PM. Scientific sessions commence at 8:00 AM on Monday, December 18, 2000. The conference program includes sessions covering the following topics: Drug Design and Discovery: Viral Targets Chemistry and Pre-Clinical Development Viral Resistance Phenotypic and Genotypic Assays Pharmacology Immunotherapy in HIV Infection First-line and Salvage Therapy Treatment Failure and Drug Interactions HIV/Hepatitis and other Co-infections Vaccines/Therapeutic Vaccines
	Organized by:	Informed Horizons, LLC
	Invited Speakers:	Edward Acosta, University of Alabama at Birmingham, USA Rafi Ahmed,Emory University School of Medicine, USA Brigitte Autran, Groupe Hospitalier Pitié-Salpetrière, France Dani Bolognesi, Trimeris, USA Martin Bryant, Novirio Pharmaceuticals, Inc, USA C.K. Chu, University of Georgia, USA Francois Clavel, Hopital Bichat-Claude Bernard, France David Cooper, University of New South Wales, Australia Lawrence Corey, University of Washington at Seattle, USA Erik De Clercq, Katholieke Universiteit Leuven, Belgium Douglas Dieterich, New York University School of Medicine, USA Anthony Fauci, NIAID, National Institutes of Health, USA Courtney Fletcher, University of Minnesota, USA Arnold Fridland, USA Klaus Frueh, RW Johnson Pharmaceutical Research Institute, USA Phillip Furman, Triangle Pharmaceuticals, USA José Gatell, Hospital Clinic, Spain John Gerber, University of Colorado, USA Martin Hirsch, Massachusetts General Hospital, USA Richard Hoetelmans, Sloltervaart Hospital, The Netherlands Eric Hunter, University of Alabama at Birmingham, USA Jean-Louis Imbach, Universite Montpellier, France Christine Katlama, Groupe Hospitalier Pitié-Salpetrière, France Paolo La Colla, Università di Cagliari, Italy Joep Lange, Academic Medical Centre, The Netherlands Brendan Larder, VIRCO, UK Franco Lori, Progetto Right Laboratori di Biotecnologie, Italy John Mellors, University of Pittsburgh, USA Tom Merigan, Stanford University, USA Julio Montaner, BC Centre for Excellence in HIV Infection, Canada Robert Murphy, Northwestern University, USA Michael Otto, Pharmasset, Inc, USA Christos Petropoulos, ViroLogic, Inc, USA Richard Pollard, University of Texas Medical Branch, USA Bruce Polsky, St Luke's-Roosevelt Hospital Center, USA Douglas Richman, University of California San Diego/VAMC, USA José Rodriguez, University of Puerto Rico, Puerto Rico Maribel Rodriguez-Torres, Fundación Gastroenterologia De Diego, Puerto Rico Walter Scott, University of Miami School of Medicine, USA Julie Strizki, Schering-Plough Pharmaceuticals, USA Stefano Vella, Istituto Superiore di Sanità, Italy Mark Wainberg, McGill University AIDS Centre, Canada Carlos Zala, Fundación Huésped, Argentina
	Deadline for Abstracts:	November 6, 2000
	Registration:	EARLY REGISTRATION Conference registration fee US $650 Accompanying guests US $230 REGULAR REGISTRATION Conference registration fee US $750 Accompanying guests US $260
	Email for Requests and Registration:	info@informedhorizons.com
	Posted by: Margie Poole   Host: client49030.atl.mediaone.net date: September 13, 2000 21:06:35 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.